|
Carcinoma
|
0.300 |
Biomarker
|
group |
CTD_human |
Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas.
|
16316942 |
2005 |
|
Animal Mammary Neoplasms
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas.
|
16316942 |
2005 |
|
Mammary Neoplasms, Experimental
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas.
|
16316942 |
2005 |
|
Anaplastic carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas.
|
16316942 |
2005 |
|
Carcinoma, Spindle-Cell
|
0.300 |
Biomarker
|
disease |
CTD_human |
Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas.
|
16316942 |
2005 |
|
Undifferentiated carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas.
|
16316942 |
2005 |
|
Carcinomatosis
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas.
|
16316942 |
2005 |
|
Mammary Carcinoma, Animal
|
0.300 |
Biomarker
|
disease |
CTD_human |
Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas.
|
16316942 |
2005 |
|
Lean body mass
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genomics of body fat percentage may contribute to sex bias in anorexia nervosa.
|
30593698 |
2019 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.
|
29892016 |
2018 |
|
Eosinophil count procedure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
|
Blood basophil count (lab test)
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
A large multiethnic genome-wide association study of prostate cancer identifies novel risk variants and substantial ethnic differences.
|
26034056 |
2015 |
|
Malignant neoplasm of prostate
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study.
|
21743467 |
2011 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study.
|
21743467 |
2011 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
The fusion protein bound avidly to the cognate antigen (the alternatively spliced EDB domain of fibronectin), retained the activity of the parental cytokine and was able to selectively localize to murine tumors in vivo, as shown by quantitative biodistribution analysis.
|
31374124 |
2020 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Reconstitution experiments using tail-vein injection and lung-to-lung metastasis in mice showed that VAMP8 was essential for RAB37-regulated vesicle trafficking of TIMP1 to suppress cancer metastasis.
|
30165196 |
2018 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Furthermore, increased VAMP8 expression was significantly correlated with tumor size (<i>p</i>=0.007), lymph node metastasis (<i>p</i>=0.024) and recurrence (<i>p</i>=0.001).
|
30607161 |
2018 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
In this review, we will summarize recent advances in fibronectin EDA and EDB-based therapeutic strategies developed to treat cancer.
|
26639577 |
2016 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Attributed to this feature, EDA and EDB domains have been extensively used for the targeted delivery of cytokines, cytotoxic agents, chemotherapy drugs and radioisotopes to fibronectin-expressing tumors to exert therapeutic effects on primary cancers and metastatic lesions.
|
26639577 |
2016 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Accordingly, treatment of Tet-FGF2 tumour-bearing animals with the neutralizing anti-murine VEGF receptor-2 antibody DC101, or of Caki-1 tumour-bearing animals with the anti-VEGF antibody bevacizumab, inhibited EDB-FN expression in tumour grafts.
|
19824060 |
2009 |
|
Malignant Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Previous experiments, based on sequential fusion of a single-chain IL12 derivative to the anti-EDB antibody fragment scFv(L19) had yielded a therapeutic fusion protein [IL12-scFv(L19)-FLAG], which displayed an impressive therapeutic activity in murine models of cancer, in spite of a tumor uptake, which was less efficient compared to the parental unmodified scFv(L19).
|
16823838 |
2006 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Previous experiments, based on sequential fusion of a single-chain IL12 derivative to the anti-EDB antibody fragment scFv(L19) had yielded a therapeutic fusion protein [IL12-scFv(L19)-FLAG], which displayed an impressive therapeutic activity in murine models of cancer, in spite of a tumor uptake, which was less efficient compared to the parental unmodified scFv(L19).
|
16823838 |
2006 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Extra domain-B containing fibronectin (EDB(+) FN), a recently proposed marker of angiogenesis, has been shown to be expressed in a number of human cancers and in ocular neovascularization in patients with proliferative diabetic retinopathy.
|
16308732 |
2005 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
All the tissues investigated produced EDA+, EDA-, EDB+ and EDB- splice variants, and this study did not support RT-PCR-based detection of either EDA or EDB domains as markers of malignancy in oral tissues.
|
9307723 |
1997 |